Literature DB >> 18684697

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

W Cacheux, T Boisserie, L Staudacher, O Vignaux, B Dousset, O Soubrane, B Terris, C Mateus, S Chaussade, F Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18684697     DOI： 10.1093/annonc/mdn540

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  22 in total

1.  Targeted therapies: bevacizumab--has it reached its final resting place?

Authors:  David J Kerr; Annie M Young
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 2.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

3.  A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.

Authors:  Philip J Aston; Gianne Derks; Balaji M Agoram; Piet H van der Graaf
Journal:  J Math Biol       Date:  2013-04-17       Impact factor: 2.259

4.  Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

Authors:  Romain Coriat; Stanislas Ropert; Olivier Mir; Bertrand Billemont; Stanislas Chaussade; Pierre-Philippe Massault; Benoit Blanchet; Olivier Vignaux; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-06-05       Impact factor: 3.850

5.  Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.

Authors:  Luca Moscetti; Fabrizio Nelli; Maria A Fabbri; Isabella Sperduti; Daniele Alesini; Enrico Cortesi; Donatello Gemma; Teresa Gamucci; Roberta Grande; Ida Pavese; Daniela Franco; Enzo M Ruggeri
Journal:  Invest New Drugs       Date:  2013-02-17       Impact factor: 3.850

6.  VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Authors:  X Bich Trinh; P A van Dam; P B Vermeulen; S J Van Laere; G G Van den Eynden; W A A Tjalma; L Y Dirix
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

Review 7.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 8.  Controlling escape from angiogenesis inhibitors.

Authors:  Barbara Sennino; Donald M McDonald
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

Review 9.  Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Authors:  John M L Ebos; Christina R Lee; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 10.  Treatment in advanced colorectal cancer: what, when and how?

Authors:  I Chau; D Cunningham
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.